Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

782 - MiR-183 is frequenty methylated and related to poor survival in human hepatocellular carcinoma


17 Dec 2016


Poster lunch


Sumadi Lukman Anwar


Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574


S.L. Anwar1, B. Hasemeier2, E. Schipper2, B. Skawran3, U. Lehmann2

Author affiliations

  • 1 Surgery, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID
  • 2 Pathology, Hannover Medical School, D-30625 - Hannover/DE
  • 3 Molecular Pathology, Hannover Medical School, D-30625 - Hannover/DE


Abstract 782


Epigenetic silencing of microRNA genes has been shown to contribute substantially in carcinogenesis including heparocellular carcinoma (HCC), the fifth most common cancer and the third leading cause of cancer mortality worldwide.


Using DNMT knockdown and microRNA microarray profiling in HCC cell lines, we then perform DNA methylation and microRNA expression analysis in primary HCC tumor samples.


Using DNMT knockdown and microRNA profiling in HCC cell lines, we found that hsa-mir-183 is upregulated after the knockdown and confirmed this with qRT-PCR. Further analysis in primary HCC specimens showed that miR-183 is hypermethylated in 30% of HCC (n = 40). Expression of mature miR-183 showed an inverse correlation with the methylation levels. In HCC cells, DNMT knockdown and 5-aza-2'-deoxycytidine treatment reduced methylation and stimulated expression of miR-183. In HCC patients, hypermethylation at miR-183 promoter significantly correlates with poor survival (log rank test p = 0.03). DNA methylation analysis in healthy liver, benign liver tumors (HCA and FNH) showed absent of hypermethylation suggesting that aberrant miR-183 methylation is specific event in liver malignancy.


Our data indicate that hypermethylation in miR-183 is a frequent event in HCC and potentially useful as a new diagnostic and prognostic marker.

Clinical trial indentification

My study is not a clinical trial.

Legal entity responsible for the study

Department of Surgery Faculty of Medicine Universitas Gadjah Mada Hannover Medical School


DFG German Science Foundation


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings